The war against the coronavirus continues and this company just announced positive results of a pilot clinical trial showing decreased production of cytokine.
Therapeutic Solutions International (OTC:TSOI) focuses on immune modulation. A recent study involving the firm’s QuadraMune has showed a significantly decreased production of the inflammatory cytokine interleukin-6, according to the company’s press release.
QuadraMune suppresses inflammatory pathways associated with COVID-19 mortality, while at the same time inhibits immune suppressive enzymes. The firm is exploring immune strategies as new variants emerge.
Shares were trading up 17 percent in afternoon trade.
